hypotensive drug

The group taking hypotensive drugs other than β blockers had a significantly lower risk than the general population.

Therefore, intervention with hypotensive drugs other than angiotensin converting enzyme inhibitors should be considered.

The other β blocker group comprised 1164 patients receiving a βblocker other than atenolol with or without hypotensive drugs of other types.

Cancers were compared in patients and controls and in patients taking atenolol, β blockers other than atenolol, and hypotensive drugs other than βblockers.

An atenolol group of 2676 patients given the drug irrespective of whether they also received other hypotensive drugs provided 16 592 patient years of exposure to atenolol (table II).

We compared the incidence of and mortality from cancer in patients of the Glasgow Blood Pressure Clinic taking atenolol and other hypotensive drugs and in two control populations.

Reference hypotensive drug choice may be critical when comparing other hypotensive drugs with angiotensin I converting enzyme inhibitors in reducing microalbuminuria in normotensive diabetic subjects.

Recently there has been speculation that the generally disappointing effects of hypotensive drug therapy in mildly hypertensive subjects may result from the deleterious metabolic side-effects of the agents themselves Multiple Risk Factor Intervention Trial Research Group (1982).